deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT01646125

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment

Sponsor: Novartis Pharmaceuticals

Updated 13 times since 2017 Last updated: Jul 11, 2019 Started: Nov 23, 2012 Primary completion: Nov 4, 2015 Completion: Nov 4, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

An interim analysis was conducted in May-2014. Upon review of the data, the committee recommended study termination due to futility.

A PHASE2 clinical study on Advanced Non Small Cell Lung Cancer (NSCLC), this trial is terminated or withdrawn. The trial is conducted by Novartis Pharmaceuticals and has accumulated 13 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~May 2018 · 9 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2019 · 14 months · monthly snapshot~Aug 2019 – ~Nov 2020 · 15 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

13 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

Show 8 earlier versions
  1. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE2

  2. Aug 2019 — Nov 2020 [monthly]

    Terminated PHASE2

  3. Jun 2018 — Aug 2019 [monthly]

    Terminated PHASE2

  4. May 2018 — Jun 2018 [monthly]

    Terminated PHASE2

  5. Aug 2017 — May 2018 [monthly]

    Terminated PHASE2

  6. May 2017 — Aug 2017 [monthly]

    Terminated PHASE2

    Status: CompletedTerminated

  7. Feb 2017 — May 2017 [monthly]

    Completed PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .